Karuna Therapeutics, Inc. Stock News

Karuna Therapeutics CEO Dr. Steve Paul appeared on Wednesday's episode of "Mad Money."

Prudential Financial Inc. boosted its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 34.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,518 shares of the companys stock after buying an additional 652 shares during the quarter. Prudential Financial Inc.s holdings in Karuna Therapeutics were []

Morgan Stanley decreased its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 26.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 73,143 shares of the companys stock after selling 26,212 shares during the quarter. Morgan Stanley owned approximately 0.25% of Karuna Therapeutics worth $8,338,000 as []

Cubist Systematic Strategies LLC cut its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 19.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,802 shares of the companys stock after selling 443 shares during the quarter. Cubist Systematic Strategies LLCs holdings in []

Karuna Therapeutics (NASDAQ:KRTX) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Earnings & Valuation This table compares Karuna Therapeutics and Pliant Therapeutics revenue, earnings per share and []

Karuna Therapeutics (NASDAQ:KRTX) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations. Risk & Volatility Karuna Therapeutics has a beta of 1.75, indicating that its share price is []

Squarepoint Ops LLC acquired a new position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,729 shares of the companys stock, valued at approximately $311,000. Several other hedge funds and other institutional investors also recently modified their holdings []

Karuna Therapeutics, Inc. (NASDAQ:KRTX) has been assigned a consensus rating of Buy from the fourteen analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered []

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Director Laurie J. Olson sold 1,000 shares of Karuna Therapeutics stock in a transaction on Monday, November 15th. The shares were sold at an average price of $138.24, for a total value of $138,240.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. []

Man Group plc reduced its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 44.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,717 shares of the companys stock after selling 13,981 shares during the quarter. Man Group plc owned approximately 0.06% of Karuna Therapeutics []

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) have been assigned an average recommendation of Buy from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and thirteen have given a buy recommendation to the company. The average 12 month price objective among []

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy